RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $820
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raised the price target from $818 to $820.
August 04, 2023 | 3:53 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Regeneron Pharmaceuticals' price target has been raised from $818 to $820 by RBC Capital, with a maintained 'Sector Perform' rating.
The news of RBC Capital raising the price target for Regeneron Pharmaceuticals and maintaining a 'Sector Perform' rating is directly related to the company. However, the slight increase in the price target may not have a significant impact on the stock's short-term price movement, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100